Veterinary Drug Interactions: Combinations to Avoid

Cytochrome P450 interactions, QT-prolonging drug combinations, NSAID stacking, MAOI hazards, and the clinically essential interaction tables every small-animal veterinarian needs — with species-specific warnings for dogs and cats.

1. Introduction: Polypharmacy and the Hidden Risks

Modern veterinary patients — especially geriatric dogs and cats — are increasingly managed on multiple medications concurrently. A 12-year-old dog with congestive heart failure, osteoarthritis, and hypothyroidism may be receiving furosemide, pimobendan, enalapril, carprofen, levothyroxine, and tramadol simultaneously. Each additional drug adds not one but a factorial increase in potential interactions: with six drugs, there are 15 possible two-drug pairs, each capable of a pharmacokinetic or pharmacodynamic interaction.

This guide identifies the clinically significant drug interactions every small-animal practitioner must recognise. It covers cytochrome P450-mediated interactions, drugs that prolong the QT interval, the dangers of NSAID stacking, monoamine oxidase inhibitor (MAOI) hazards, and species-specific toxicities unique to cats. Each interaction is accompanied by a practical management recommendation, not just a warning.

2. Cytochrome P450 Interactions

The cytochrome P450 (CYP) enzyme superfamily is responsible for the phase I metabolism of approximately 75% of clinically used drugs. In dogs, the most clinically relevant CYP isoforms are CYP3A12 (the canine orthologue of human CYP3A4), CYP2B11, CYP2D15, and CYP2C21. In cats, CYP2E1 and CYP1A2 are particularly important, and cats have significantly lower activity of several CYP isoforms compared to dogs — including the glucuronidation pathway, which makes them uniquely vulnerable to certain toxicities.

2.1 P-glycoprotein Interactions

P-glycoprotein (P-gp) is an efflux transporter that pumps drugs out of cells, including out of the brain at the blood–brain barrier and out of enterocytes into the gut lumen. Drugs that inhibit P-gp can dramatically increase CNS penetration of P-gp substrates, causing neurotoxicity.

• Ivermectin neurotoxicity in dogs with the MDR1 mutation (Collies, Australian Shepherds, and related breeds) is the classic veterinary P-gp example, but pharmacologic P-gp inhibition (ketoconazole, cyclosporine, diltiazem) can produce the same effect in non-mutant dogs at high ivermectin doses.
• Loperamide is a P-gp substrate normally excluded from the CNS — concurrent administration of a P-gp inhibitor (ketoconazole, quinidine) can cause respiratory depression and CNS sedation from loperamide.

3. QT-Prolonging Drugs: The Risk of Torsades de Pointes

Drug-induced QT prolongation delays ventricular repolarisation and predisposes to torsades de pointes — a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. The risk is highest when multiple QT-prolonging drugs are combined, or when a QT-prolonging drug is given to a patient with hypokalaemia, hypomagnesaemia, bradycardia, or pre-existing cardiac disease.

Clinical rule: Do not prescribe more than one QT-prolonging drug simultaneously unless no alternative exists. If two are required, obtain a baseline ECG, correct electrolyte abnormalities (K⁺ > 4.0 mmol/L, Mg²⁺ > 0.8 mmol/L), and monitor ECG 2–4 hours after each dose adjustment.

4. NSAID Interactions: Stacking, Steroids, and Systemic Consequences

Non-steroidal anti-inflammatory drugs are the most commonly prescribed analgesics in small-animal practice, and also the drug class most frequently involved in serious interactions. The two cardinal rules: never combine two NSAIDs, and never combine an NSAID with a corticosteroid.

4.1 The Washout Rule

When transitioning from one NSAID to another, or between an NSAID and a corticosteroid, a minimum washout period of 5–7 days is required. During the washout period, provide alternative analgesia if needed: opioids (buprenorphine, tramadol — with the CYP caveats above), gabapentin, amantadine, or paracetamol (dogs only — 10–15 mg/kg PO q8h; not for cats).

4.2 Species-Specific NSAID Warnings

• Cats: Cats eliminate NSAIDs slowly due to deficient glucuronidation. Meloxicam is licensed for single-dose use (0.3 mg/kg SC) in cats in some countries; repeated dosing must be at the reduced 'chronic feline' dose (0.05 mg/kg PO q24h) for no more than 4–5 days. Do not use carprofen in cats except as a single perioperative dose (2–4 mg/kg SC/IV once).
• Greyhounds: Greyhounds and related sighthounds may have altered NSAID pharmacokinetics. Use the lowest effective dose and monitor closely.
• Dogs with hepatic disease: Carprofen and meloxicam undergo hepatic metabolism. Use reduced doses or select an NSAID with primarily renal elimination (tepoxalin — though less commonly available).

5. MAOIs, SSRIs, and the Serotonergic Spectrum

Serotonin syndrome is an acute, life-threatening condition caused by excessive serotonergic activity in the CNS and periphery. It ranges from mild (restlessness, mydriasis, diarrhoea) to severe (hyperthermia, rigidity, seizures, DIC, death). In veterinary medicine, it most commonly results from drug interactions involving the MAOI selegiline, the SSRI fluoxetine, the TCA clomipramine, or tramadol.

5.1 Washout Periods for Psychotropic Drugs in Dogs

• Fluoxetine → selegiline: 5 weeks minimum (fluoxetine + norfluoxetine half-life).
• Selegiline → fluoxetine: 2 weeks minimum (selegiline is an irreversible MAOI — new MAO must be synthesised).
• Clomipramine → selegiline: 2 weeks minimum.
• Selegiline → clomipramine: 2 weeks minimum.

6. The Interaction Tables Every Clinician Needs

Below is a rapid-reference table of common drug combinations, their clinical significance, and the recommended action. Post this in your pharmacy or consult room.

7. Species-Specific Feline Toxicities

Cats are not small dogs. Their unique metabolic profile — deficient glucuronidation, slow acetylation, and limited activity of several CYP isoforms — makes them exquisitely sensitive to drugs that are well-tolerated by dogs and humans. The following drugs should never be administered to cats, or only with extreme caution:

8. Clinical Decision Algorithm: Adding a Drug to a Polypharmacy Patient

When adding a new medication to a patient already receiving chronic therapy, follow this algorithm:

1. List all current medications — including doses, frequency, and duration. Include over-the-counter supplements and topical products (flea/tick control).
2. Check for known interactions — use the tables in this guide, Plumb's, or an electronic interaction checker. Pay particular attention to CYP450 interactions and QT-prolonging potential.
3. Assess organ function — if the patient has hepatic or renal impairment, drug clearance may be reduced, amplifying the risk of any interaction.
4. Start low, go slow — initiate the new drug at the lowest effective dose. Schedule a recheck (including relevant lab work) within 3–7 days to assess for toxicity or altered efficacy of existing medications.
5. Document — record the rationale for the new drug, the interaction check, and the monitoring plan in the medical record. If a known interaction is accepted (e.g. intentional ketoconazole + cyclosporine), document the reasoning and the monitoring protocol.

Frequently asked questions

Self-check quiz

Test yourself. Answers are below each question — cover them first if you are studying.